What is HC Wainwright’s Forecast for DMRA FY2026 Earnings?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) – Equities researchers at HC Wainwright lowered their FY2026 EPS estimates for Damora Therapeutics, Inc. Common Stock in a report issued on Thursday, November 5th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($1.73) for the year, down from their prior estimate of ($1.67). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Damora Therapeutics, Inc. Common Stock’s current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Damora Therapeutics, Inc. Common Stock’s Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.42) EPS and FY2027 earnings at ($1.70) EPS.

Several other research firms have also commented on DMRA. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Finally, Wall Street Zen upgraded Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a report on Sunday. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $46.38.

Damora Therapeutics, Inc. Common Stock Stock Up 0.3%

DMRA stock opened at $24.15 on Monday. Damora Therapeutics, Inc. Common Stock has a 52-week low of $15.00 and a 52-week high of $38.33. The stock’s fifty day simple moving average is $22.54 and its 200-day simple moving average is $25.65. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.17 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.12.

Insider Activity at Damora Therapeutics, Inc. Common Stock

In other news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the transaction, the chief executive officer owned 512,500 shares of the company’s stock, valued at $10,367,875. This represents a 2.50% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $303,000. Arizona State Retirement System acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $260,000. Seven Fleet Capital Management LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $7,398,000. Finally, Braidwell LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.